CovidResearchTrials by Shray Alag


CovidResearchTrials Covid 19 Research using Clinical Trials (Home Page)


Chloroquine Phosphate TabletsWiki

Developed by Shray Alag
Clinical Trial MeSH HPO Drug Gene SNP Protein Mutation


Correlated Drug Terms (0)


Name (Synonyms) Correlation

Correlated MeSH Terms (1)


Name (Synonyms) Correlation
D011014 Pneumonia NIH 0.06

Correlated HPO Terms (1)


Name (Synonyms) Correlation
HP:0002090 Pneumonia HPO 0.06

There is one clinical trial.

Clinical Trials


1 Phase II, Randomized, Double-blind, Controlled Clinical Trial Evaluating the Efficacy and Safety of Chloroquine + Low Dose Losartan Compared to Chloroquine Monotherapy in Subjects With SARS-CoV-2 Pneumonia

Study design Phase 2, double blinded, single-center, 1:1 randomized clinical trial of Chloroquine vs Chloroquine/losartan for the treatment of SARS-CoV-2 pneumonia in non-critically ill subjects

NCT04428268 COVID-19 Pneumonia Drug: Chloroquine Phosphate Tablets
MeSH:Pneumonia
HPO:Pneumonia

Primary Outcomes

Description: Determine all-cause mortality up to 28 days after randomization of Chloroquine Phosphate Compared to Chloroquine Phosphate plus Losartan in Non-Critically Ill Patients with SARS-CoV-2 Pneumonia.

Measure: Overall mortality

Time: 28 days

Secondary Outcomes

Description: Compare the clinical outcome of Chloroquine Phosphate treatment vs Chloroquine Phosphate plus Losartan in the follow-up visit at the end of treatment. Acording to NIH and FDA definitions

Measure: Clinical outcome assessment

Time: 28 days

Description: Assess the adverse events associated to chloroquine and chloroquine plus losartan at 28 days

Measure: Number of participants with treatment-related adverse events as assessed by CTCAE v4.0

Time: 28 days

Description: Time to negative Polymerase chain reaction (PCR) test from baseline: testing every 48hrs until a negative result

Measure: Time to negative SARS-CoV-2 test

Time: 28 days


Related HPO nodes (Using clinical trials)